Physician profile
Sonal Pathak
NPI 1801020524
$3,374.07
in general payments reported to CMS, 2019-2025
30 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $350 · 2021: $101 · 2022: $329 · 2023: $36.40 · 2024: $345 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,554.93 | 2019-2025 | Evenity, Tepezza |
| Astrazeneca Pharmaceuticals Lp | $225.66 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $186.49 | 2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $173.84 | 2019-2020 | |
| Medtronic, INC. | $162.91 | 2024-2025 | Minimed 780g |
| Lilly USA, LLC | $162.76 | 2019-2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $107.31 | 2020-2021 | |
| Insulet Corporation | $60.56 | 2020-2025 | Omnipod |
| Kyowa Kirin, INC. | $57.01 | 2025 | |
| Merck Sharp & Dohme LLC | $56.96 | 2019-2020 | |
| Corcept Therapeutics | $56.18 | 2025 | Korlym |
| Abbvie INC. | $52.75 | 2019-2020 | |
| Novo Nordisk INC | $49.87 | 2019-2020 | |
| Cequr Corporation | $49.13 | 2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.00 | 2019-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $47.61 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.13 | 2019 | |
| Pfizer INC. | $39.56 | 2019 | |
| Ascensia Diabetes Care US INC. | $32.12 | 2025 | |
| Beta Bionics, INC. | $27.98 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Shire North American Group INC | $26.91 | 2019 | |
| Senseonics, Incorporated | $24.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.97 | 2019 | |
| Averitas Pharma INC. | $18.92 | 2025 | Qutenza |
| Recordati_rare_diseases_inc. | $18.27 | 2025 | Isturisa |
| Amneal Pharmaceuticals LLC | $15.15 | 2025 | Unithroid |
| Horizon Therapeutics Plc | $14.90 | 2023 | Tepezza |
| Mannkind Corporation | $13.89 | 2020 | |
| Amarin Pharma, INC. | $13.32 | 2019 | |
| Becton, Dickinson and Company | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonal Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.